Skip header and navigation

Refine By

769 records – page 1 of 77.

10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients.

https://arctichealth.org/en/permalink/ahliterature141809
Source
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1323-9
Publication Type
Article
Date
Aug-1-2011
Author
Juanita Crook
Jette Borg
Andrew Evans
Ants Toi
E P Saibishkumar
Sharon Fung
Clement Ma
Author Affiliation
Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada. jcrook@bccancer.bc.ca
Source
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1323-9
Date
Aug-1-2011
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - blood - mortality - pathology - radiotherapy
Aged
Aged, 80 and over
Brachytherapy - adverse effects - methods
Disease-Free Survival
Humans
Iodine Radioisotopes - therapeutic use
Male
Middle Aged
Neoadjuvant Therapy - methods
Neoplasm Staging
Ontario
Penile Erection - physiology
Proportional Hazards Models
Prospective Studies
Prostate
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood - mortality - pathology - radiotherapy
Radiotherapy Dosage
Urination Disorders - drug therapy
Abstract
To report outcomes for 1,111 men treated with iodine-125 brachytherapy (BT) at a single institution.
A total of 1,111 men (median age, 63) were treated with iodine-125 prostate BT for low- or intermediate-risk prostate cancer between March 1999 and November 2008. Median prostate-specific antigen (PSA) level was 5.4 ng/ml (range, 0.9-26.1). T stage was T1c in 66% and T2 in 34% of patients. Gleason score was 6 in 90.1% and 7 or 8 in 9.9% of patients. Neoadjuvant hormonal therapy (2-6 months course) was used in 10.1% of patients and combined external radiotherapy (45 Gy) with BT (110 Gy) in 4.1% (n = 46) of patients. Univariate and multivariate Cox proportional hazards were used to determine predictors of failure.
Median follow-up was 42 months (range, 6-114), but for biochemical freedom from relapse, a minimum PSA test follow-up of 30 months was required (median 54; n = 776). There were 27 failures, yielding an actuarial 7-year disease-free survival rate of 95.2% (96 at risk beyond 84 months). All failures underwent repeat 12-core transrectal ultrasound -guided biopsies, confirming 8 local failures. On multivariate analysis, Gleason score was the only independent predictor of failure (p = 0.001; hazard ratio, 4.8 (1.9-12.4). Median International Prostate Symptom score from 12 to 108 months ranged between 3 and 9. Of the men reporting baseline potency, 82.8% retained satisfactory erectile function beyond 5 years.
Iodine-125 prostate BT is a highly effective treatment option for favorable- and intermediate-risk prostate cancer and is associated with maintenance of good urinary and erectile functions.
PubMed ID
20675072 View in PubMed
Less detail

A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.

https://arctichealth.org/en/permalink/ahliterature162371
Source
Biol Blood Marrow Transplant. 2007 Aug;13(8):956-64
Publication Type
Article
Date
Aug-2007
Author
Mitchell Sabloff
Harold L Atkins
Isabelle Bence-Bruckler
Christopher Bredeson
Dean Fergusson
Paul Genest
Harry Hopkins
Brian Hutton
Sheryl Mcdiarmid
Lothar B Huebsch
Author Affiliation
The Ottawa Hospital Blood and Marrow Transplant Program, University of Ottawa, Ottawa, Ontario, Canada. msabloff@ottawahospital.on.ca
Source
Biol Blood Marrow Transplant. 2007 Aug;13(8):956-64
Date
Aug-2007
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Disease-Free Survival
Female
Hematopoietic Stem Cell Transplantation - adverse effects - methods
Humans
Longitudinal Studies
Lymphoma, Follicular - therapy
Male
Middle Aged
Neoplasm Recurrence, Local - therapy
Ontario
Retrospective Studies
Salvage Therapy - methods
Transplantation, Autologous - methods
Abstract
Autologous stem cell transplant (ASCT) has been shown to be an effective treatment for follicular lymphoma (FL). We explored our experience in ASCT for FL among all patients treated over a 15-year period from diagnosis through their entire treatment history including relapse post ASCT. All patients who underwent an unpurged ASCT for relapsed, advanced FL between June 1990 and December 2000 were analyzed. After salvage therapy they received melphalan/etoposide/total body irradiation, BCNU, etoposide, cytarabine, melphalan (BEAM), or cyclophosphamide BCNU etoposide (CBV) as conditioning for the ASCT. One hundred thirty-eight patients with a median age of 48 years and a median follow-up of 7.6 years were analyzed. The majority were of the subtype grade 1, nontransformed (FL-NT), having had 1 prior chemotherapy. The progression-free (PFS) and overall survival (OS) of the FL-NT at 10 years were 46% and 57%, respectively, and at 5 years for the transformed (FL-T) were 25% and 56%, respectively, of which only the PFS was significantly different (P=.007). The median OS from diagnosis was 16 years for the FL-NT. ASCT positively altered the trend of shorter remissions with subsequent chemotherapies, and there was no difference in OS between those who had 1, 2, or >2 chemotherapies prior to ASCT. Salvage therapy for relapse post ASCT was effective (OS>1 year) in a third of patients. Unpurged ASCT is an effective tool in the treatment of relapsed, aggressive FL-NT and FL-T, is superior to retreatment with standard chemotherapy, is effective at various stages of treatment, is likely to have a beneficial influence on the natural history of this disease, and the disease is amenable to salvage therapy post-ASCT relapse.
PubMed ID
17640600 View in PubMed
Less detail

[20-year experience with modified dose fractionation of radiotherapy in primary Hodgkin's disease].

https://arctichealth.org/en/permalink/ahliterature154608
Source
Vopr Onkol. 2008;54(4):529-31
Publication Type
Article
Date
2008
Author
N V Il'in
E N Nikolaeva
E V Smirnova
Iu N Vinogradova
E I Ivanova
B M Izotov
I A Shenderova
Source
Vopr Onkol. 2008;54(4):529-31
Date
2008
Language
Russian
Publication Type
Article
Keywords
Adult
Aged
Biomedical research
Disease-Free Survival
Dose Fractionation
Female
Hodgkin Disease - radiotherapy
Humans
Incidence
Kaplan-Meier Estimate
Leukopenia - epidemiology - etiology
Male
Middle Aged
Pericarditis - epidemiology - etiology
Pneumonia - epidemiology - etiology
Radiotherapy - adverse effects
Recurrence
Retrospective Studies
Russia - epidemiology
Severity of Illness Index
Thrombocytopenia - epidemiology - etiology
Treatment Outcome
Abstract
Significantly lower frequency of relapse, incidence of pulmonitis and pericarditis, leukopenia and thrombocytopenia stage IV and longer recurrence-free survival were reported after acceleration of multifractionation of STD of 1.35Gy was used for treatment of patients with primary Hodgkin's disease, as compared with standard fractionation. When STD was reduced to 1.2Gy (modified multifractionation), subtotal exposure of lymph nodes was followed by a significant drop in frequency and severity of leukopenia and thrombocytopenia stage III-IV. The latter complications, rates decreased further, with perspective response to therapy, as irradiation was limited to that of areas exposed during modified multifractionation.
PubMed ID
18942416 View in PubMed
Less detail

5993 survivors of suspected myocardial infarction. 10 year incidence of later myocardial infarction and subsequent mortality.

https://arctichealth.org/en/permalink/ahliterature54402
Source
Eur Heart J. 1998 Apr;19(4):564-9
Publication Type
Article
Date
Apr-1998
Author
S. Galatius
J. Launbjerg
L S Mortensen
J F Hansen
Author Affiliation
Department of Medicine B. National University Hospital, Rigshospitalet, Copenhagen, Denmark.
Source
Eur Heart J. 1998 Apr;19(4):564-9
Date
Apr-1998
Language
English
Publication Type
Article
Keywords
Adult
Age Distribution
Aged
Cause of Death
Confidence Intervals
Coronary Care Units
Denmark - epidemiology
Disease-Free Survival
Female
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
Myocardial Infarction - diagnosis - mortality
Proportional Hazards Models
Recurrence
Research Support, Non-U.S. Gov't
Retrospective Studies
Risk factors
Sex Distribution
Survival Rate
Treatment Outcome
Abstract
AIMS: To evaluate the 10-year incidence of later infarction and subsequent mortality, as well as predictors of later infarction, in patients with suspected myocardial infarction and alive on day 15 after admission. METHODS AND RESULTS: 5993 patients admitted with suspected myocardial infarction and alive on day 15 after admission were registered in The First Danish Verapamil Infarction Trial database in 1979-81. 2586 had definite infarction, 402 probable infarction and 3005 no infarction as they fulfilled 3, 2 and 1 criteria for infarction. They were followed for 10 years with respect to later infarction and death, i.e., including death after later infarction. The 10 year infarction rate after index admission was 48.8% in definite, 47.3% in probable and 24.6% in no infarction patients (P 65 years with definite or probable infarction. CONCLUSION: The 10-year infarction rate in patients with suspected myocardial infarction in whom the diagnosis is ruled out is lower than in those with definite or probable infarction, but the mortality after a later infarction is similar in all three groups.
Notes
Comment In: Eur Heart J. 1998 Apr;19(4):534-59597397
PubMed ID
9597404 View in PubMed
Less detail

Ablation for atrial fibrillation during mitral valve surgery: 1-year results through continuous subcutaneous monitoring.

https://arctichealth.org/en/permalink/ahliterature125117
Source
Interact Cardiovasc Thorac Surg. 2012 Jul;15(1):37-41
Publication Type
Article
Date
Jul-2012
Author
Alexandr Bogachev-Prokophiev
Sergey Zheleznev
Alexander Romanov
Evgeny Pokushalov
Alexey Pivkin
Giorgio Corbucci
Alexander Karaskov
Author Affiliation
Department of Heart Valves Surgery, State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation. b-pav@rambler.ru
Source
Interact Cardiovasc Thorac Surg. 2012 Jul;15(1):37-41
Date
Jul-2012
Language
English
Publication Type
Article
Keywords
Atrial Fibrillation - complications - diagnosis - mortality - surgery
Atrial Flutter - diagnosis - etiology - mortality
Catheter Ablation - adverse effects - mortality
Chi-Square Distribution
Disease-Free Survival
Electrocardiography, Ambulatory
Female
Heart Valve Diseases - complications - mortality - surgery
Heart Valve Prosthesis Implantation - adverse effects - mortality
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Mitral Valve - surgery
Predictive value of tests
Prospective Studies
Recurrence
Risk assessment
Risk factors
Russia
Time Factors
Treatment Outcome
Abstract
Continuous monitoring of cardiac rhythm may play an important role in measuring the true symptomatic/asymptomatic atrial fibrillation (AF) burden and improve the management of anti-arrhythmic and anti-thrombotic therapies. Forty-seven patients with mitral valve disease and longstanding persistent AF (LSPAF) underwent a left atrial maze procedure with bipolar radiofrequency and valve surgery. The follow-up data recorded by an implanted loop recorder were analysed after 3, 6 and 12 months. On discharge, 40 (85.1%) patients were in stable sinus rhythm, as documented by in-office electrocardiography (ECG), 4 (8.5%) were in pacemaker rhythm and 3 (6.4%) were in AF. One (2.1%) patient died after 7 months. On 12-month follow-up examination, 30 (65.2%) patients had an AF burden 0.5%. Two (4.3%) patients with AF recurrences were completely asymptomatic. Among the symptomatic events stored by the patients, only 27.6% was confirmed as genuine AF recurrences according to the concomitant ECG recorded by the implanted loop recorder. A concomitant bipolar maze procedure during mitral valve surgery is effective in treating AF, as proved by detailed 1-year continuous monitoring.
Notes
Cites: Heart Rhythm. 2007 Jun;4(6):816-6117556213
Cites: Eur J Cardiothorac Surg. 2008 Apr;33(4):590-518243722
Cites: Asian Cardiovasc Thorac Ann. 2008 Aug;16(4):292-718670021
Cites: Circulation. 2008 Oct 7;118(15):e523-66118820172
Cites: Ann Thorac Surg. 2009 Jul;88(1):101-519559203
Cites: J Thorac Cardiovasc Surg. 2007 Apr;133(4):1037-4417382650
Cites: Circ Arrhythm Electrophysiol. 2010 Apr;3(2):141-720160169
Cites: Eur J Cardiothorac Surg. 2011 Aug;40(2):405-1121601472
Cites: J Am Coll Cardiol. 2000 Jan;35(1):183-710636278
Cites: Ann Thorac Surg. 2007 Mar;83(3):1225-3017307507
Cites: Ann Thorac Surg. 2007 Apr;83(4):1319-2417383333
Cites: Circulation. 2009 Sep 15;120(11 Suppl):S177-8419752365
PubMed ID
22514258 View in PubMed
Less detail

Abnormal DNA content predicts the occurrence of carcinomas in non-dysplastic oral white patches.

https://arctichealth.org/en/permalink/ahliterature19552
Source
Oral Oncol. 2001 Oct;37(7):558-65
Publication Type
Article
Date
Oct-2001
Author
J. Sudbø
T. Ried
M. Bryne
W. Kildal
H. Danielsen
A. Reith
Author Affiliation
Division of Digital Pathology, Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo 0310, Norway. jon.sudbo@rh.uio.no
Source
Oral Oncol. 2001 Oct;37(7):558-65
Date
Oct-2001
Language
English
Publication Type
Article
Keywords
Adult
Aged
Carcinoma, Squamous Cell - diagnosis - genetics
DNA, Neoplasm - analysis
Disease-Free Survival
Female
Follow-Up Studies
Humans
Image Cytometry - methods
Male
Middle Aged
Mouth Neoplasms - diagnosis - genetics
Ploidies
Precancerous Conditions - diagnosis - genetics
Prognosis
Research Support, Non-U.S. Gov't
Tumor Markers, Biological - analysis
Abstract
The majority of oral squamous cell carcinomas (OSCCs) are preceded by visible changes in the oral mucosa, most often white patches. Although the histological finding of dysplasia in oral white patches signals increased risk of developing OSCC, this may also occur in non-dysplastic lesions. However, no reliable markers exist to predict the occurrence of OSCC in these patients. From a total of 263 patients diagnosed with oral white patches, biopsies from 45 patients were selected on the criteria that the patients had lesions histologically proven to be non-dysplastic. The lesions were analyzed with respect to their DNA content. The clinical outcome of the patients was known from the Cancer Registry of Norway, and these data were compared to the DNA content of their lesions. Among the 45 patients, five cases (11%) later developed an OSCC. Four of the cases that subsequently developed an OSCC were among the five aneuploid (abnormal) cases (P=0.001). One aneuploid lesion did not develop a carcinoma during a follow-up time of 120 months. The fifth case that subsequently developed an OSCC was diploid (normal), and developed into an OSCC after an observation time of 73 months (P=0.001). In conclusion, aberrant DNA content reliably predicts the occurrence of OSCC in patients that otherwise would be regarded as at very low risk. Normal DNA content indicates low risk.
PubMed ID
11564576 View in PubMed
Less detail

Acute de novo Leukemia in Estonia and Western Sweden 1982-2006: Positive Trend in the Survival of Acute Leukemia over 25 Years.

https://arctichealth.org/en/permalink/ahliterature278078
Source
Acta Haematol. 2016;136(3):167-73
Publication Type
Article
Date
2016
Author
Erik Hulegårdh
Mari Punab
Erik Holmberg
Katrin Palk
Edward Laane
Hele Everaus
Lovisa Wennström
Dick Stockelberg
Source
Acta Haematol. 2016;136(3):167-73
Date
2016
Language
English
Publication Type
Article
Keywords
Acute Disease
Adolescent
Adult
Disease-Free Survival
Estonia - epidemiology
Female
Hematopoietic Stem Cell Transplantation
Humans
Leukemia - diagnosis - mortality - therapy
Male
Middle Aged
Prospective Studies
Retrospective Studies
Socioeconomic Factors
Survival Rate
Sweden - epidemiology
Abstract
This study focuses on the incidence, treatment, and survival of de novo acute leukemia in a 25-year perspective in western Sweden and Estonia. At the beginning of our study, Estonia was a part of the Eastern bloc with planned economy, but since 1991 it is a member of the European Union and transforming into a market economy. Survival rates have steadily increased in both countries. However, a gap between their survival curves remains. Based on our data, it is difficult to explain the big difference in the 5-year relative survival in favor of western Sweden (55 vs. 22%). In Germany, there was a big difference in overall cancer survival between East and West Germany after the fall of the iron curtain, but today no difference is seen. Differences in survival are probably due to a higher proportion of intense chemotherapy regimens and a higher rate of hematopoietic stem cell transplantations in Sweden. Other important factors might be better supportive care and diagnostics as well as better adjuvant therapy. Better staff training and conditions in wards are also factors that might play an essential role.
PubMed ID
27537981 View in PubMed
Less detail

Acute leukaemia in children with Down syndrome: a population-based Nordic study.

https://arctichealth.org/en/permalink/ahliterature17162
Source
Br J Haematol. 2005 Mar;128(6):797-804
Publication Type
Article
Date
Mar-2005
Author
Bernward Zeller
Göran Gustafsson
Erik Forestier
Jonas Abrahamsson
Niels Clausen
Jesper Heldrup
Liisa Hovi
Gudmundur Jonmundsson
Sverre O Lie
Anders Glomstein
Henrik Hasle
Author Affiliation
Department of Paediatrics, National Hospital of Norway, N-0027 Oslo, Norway. bem.zeller@rikshospitalet.no
Source
Br J Haematol. 2005 Mar;128(6):797-804
Date
Mar-2005
Language
English
Publication Type
Article
Keywords
Acute Disease
Age Distribution
Child
Child, Preschool
Disease-Free Survival
Down Syndrome - complications - epidemiology - therapy
Female
Humans
Infant
Infant, Newborn
Leukemia, Lymphocytic, Acute, L1 - complications - epidemiology - therapy
Leukemia, Myeloid - complications - epidemiology - therapy
Male
Norway - epidemiology
Research Support, Non-U.S. Gov't
Abstract
To determine the epidemiology and outcome of children with Down syndrome (DS) diagnosed with acute leukaemia in the Nordic countries, data registered in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) population-based leukaemia registry were analysed. Of 3494 children with acute leukaemia diagnosed between July 1984 and December 2001, 136 patients (3.9%) with DS were identified. 2.1% of the children with acute lymphoid leukaemia (ALL) and 14.0% of the children with acute myeloid leukaemia (AML) had DS. In ALL, DS patients had similar age and sex distribution and no major differences in blood counts compared with non-DS children. None of the DS patients had T cell leukaemia. Outcome was inferior to that of non-DS children and treatment results did not improve over time. In AML, DS patients showed a significant female predominance and all but one were
PubMed ID
15755283 View in PubMed
Less detail

Acute lymphoblastic leukemia in adolescents and young adults in Finland.

https://arctichealth.org/en/permalink/ahliterature92984
Source
Haematologica. 2008 Aug;93(8):1161-8
Publication Type
Article
Date
Aug-2008
Author
Usvasalo Anu
Räty Riikka
Knuutila Sakari
Vettenranta Kim
Harila-Saari Arja
Jantunen Esa
Kauppila Marjut
Koistinen Pirjo
Parto Katriina
Riikonen Pekka
Salmi Toivo T
Silvennoinen Raija
Elonen Erkki
Saarinen-Pihkala Ulla M
Author Affiliation
Hospital for Children and Adolescents, University of Helsinki, P.O. Box 281, 00029 HUS, Helsinki, Finland. anu.usvasalo@helsinki.fi
Source
Haematologica. 2008 Aug;93(8):1161-8
Date
Aug-2008
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Antineoplastic Agents - therapeutic use
Blast Crisis
Child
Disease-Free Survival
Female
Finland
Humans
Leukemia-Lymphoma, Adult T-Cell - drug therapy - genetics - mortality - pathology
Leukocyte Count
Male
Phenotype
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy - genetics - mortality - pathology
Survival Analysis
Abstract
BACKGROUND: Interest has recently been paid to adolescents and young adults with acute lymphoblastic leukemia, particularly because all reports so far published indicate that these patients have a better outcome when treated with pediatric rather than adult therapeutic protocols. There are different biological subtypes of acute lymphoblastic leukemia with distinct features and prognoses; the distribution of these subtypes is not well known among adolescents. We, therefore, studied acute lymphoblastic leukemia in adolescents and young adults aged 10 to 25 years in Finland. DESIGN AND METHODS: This population-based study included 225 consecutive patients aged 10-25 years diagnosed with acute lymphoblastic leukemia during 1990-2004. One hundred and twenty-eight patients (10-16 years) were treated with pediatric Nordic (NOPHO) protocols, and 97 patients (17-25 years) with Finnish Leukemia Group National protocols. We characterized the biological subtypes, clinical features and outcome of these patients. RESULTS: For the whole cohort, the remission rate was 96%, 5-year event-free survival 62% and overall survival 72%.The 5-year event-free survival was 67% for the pediatric treatment group and 60% for the adult treatment group (p=n.s.). Patients with inferior outcome were those with a white blood cell count >or= 100 x 10(9)/L, the Philadelphia chromosome and MLL. Good prognostic features were TEL-AML1, hyperdiploidy, and pediatric intermediate risk stratification. CONCLUSIONS: Unlike all previous studies, we found that the outcome of adolescents and young adults with acute lymphoblastic leukemia treated with pediatric or adult therapeutic protocols was comparable. The success of the adult acute lymphoblastic leukemia therapy emphasizes the benefit of central referral of patients to academic centers and adherence to research protocols.
Notes
Comment In: Haematologica. 2008 Aug;93(8):1124-818669975
PubMed ID
18556413 View in PubMed
Less detail

769 records – page 1 of 77.